PharmD '08 University of Pittsburgh; PhD '13 University of North Carolina at Chapel Hill
The long-term goal of my lab is to improve pharmacologic outcomes and reduce racial disparities in patients with cardiovascular disease, especially patients with heart failure. I use a variety of clinical & translational approaches to achieve that goal, including the use of existing clinical/genomic databases, electronic medical records, and clinical studies. Genetics is a major focus of my lab.
Luzum JA, Peterson E, Li J, She R, Pinto YM, Williams LK, Sabbah HN, and *Lanfear DE. Race and beta-blocker survival benefit in patients with heart failure: an investigation of self-reported African American race and African genetic ancestry. Journal of the American Heart Association. 2018; 7(10). pii: e007956. [PMID: 29739794]
Luzum JA, Sweet K, Binkley PF, Sadee W, and Kitzmiller JP. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure. Pharmaceutical Research. 2017;34(8):1615-1625. [PMID: 28181117; PMCID: PMC5500390]
Luzum JA, Kitzmiller JP, Isackson PJ, Ma CX, Medina MW, Dauki AM, Mikulik EB, Ochs-Balcom HM, and Vladutiu GD. GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. Cell Metabolism. 2015; 21(4):622-7. [PMID: 25863251]
Luzum JA, Theusch E, Taylor KD, Wang A, Sadee W, Binkley PF, Krauss RM, Medina MW, and Kitzmiller JP. Individual and combined associations of genetic variants in CYP3A4, CYP3A5, and SLCO1B1 with simvastatin and simvastatin acid plasma concentrations. Journal of Cardiovascular Pharmacology. 2015; 66(1):80-5. [PMID: 26164721]
Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Schildcrout JS, Pulley JM, Beller M, Field JR, Weitzel KW, Cooper-DeHoff RM, Cavallari LH, O’Donnell PH, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, *Freimuth RR, for the Pharmacogenomics Research Network Translational Pharmacogenetics Program. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clinical Pharmacology & Therapeutics. 2017;102(3):502-510 [PMID: 28090649]